Gene-editing biotech that co-developed Casgevy, the first approved CRISPR therapy, for sickle cell disease and beta-thalassemia.
Gene-editing biotech that co-developed Casgevy, the first approved CRISPR therapy, for sickle cell disease and beta-thalassemia.
Does not sell Casgevy itself: Vertex runs commercialisation and the two split costs and profits, so CRISPR's income depends on how many patients complete the lengthy treatment process at authorised centres. Beyond that it funds research from its cash reserves, with in-house gene-editing programmes for heart disease and diabetes.
Moat: narrow (IP / patents, process know-how). A foundational CRISPR/Cas9 patent estate and being first to market with an approved gene-editing cure.
Headquarters: Zug, Switzerland · Founded: 2013
Size CRISPR Therapeutics (CRSP) is a United States Health Care company (Biotechnology) with a market value of $3.90B, the 1353rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $40.19 on 18 Nov 2026.
Performance Over six months the shares fell 17.2%, against +2.0% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue fell 34.3% over the last twelve months (peer median +6.3%); the operating margin is -2,058.6% (peer median -3.6%).
Valuation It trades at 95.6× enterprise value to sales against a peer median of 8.3× (4th most expensive of 16).
Short interest Short interest is 17.7% of the free float (30 Oct 2026).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $25.2M | $3.51M | $37.3M | $371M | $1.20M |
| Revenue growth | — | -91% | -90% | +30,885% | — |
| Gross profit | -$174M | -$229M | -$92.2M | $221M | -$133M |
| EBITDA | -$500M | -$549M | -$447M | -$203M | -$649M |
| Net income | -$456M | -$582M | -$366M | -$154M | -$650M |
| Free cash flow | -$377M | -$346M | -$145M | -$270M | -$533M |
| Capital expenditure | $2.08M | $914,000 | $1.90M | $9.47M | $37.2M |
| Total debt | $780M | $207M | $224M | $239M | $244M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| CRISPR Therapeutics CRSP | $3.90B | -17% | -34% | -2,059% | 95.6× | n/a |
| Intellia Therapeutics NTLA | $1.37B | -20% | -8% | -821% | 21.3× | n/a |
| Editas Medicine EDIT | n/a | -32% | n/a | n/a | n/a | n/a |
| Vertex Pharmaceuticals VRTX | $136B | +25% | +11% | 35% | 10.5× | 6.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CRSP | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.4% | -5.3% | 3rd lowest of 21 |
| 6-month return | -17.2% | +2.0% | 4th lowest of 21 |
| Distance from 52-week high | -36.7% | -31.1% | 7th lowest of 21 |
| Revenue growth (TTM) | -34.3% | +6.3% | 3rd lowest of 17 |
| Operating margin | -2,058.6% | -3.6% | 4th lowest of 16 |
| EV / Sales | 95.6× | 8.3× | 4th most expensive of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics CRSP | United States | $3.90B | -17% | -34% | -2,059% | 95.6× | n/a | n/a |
| Lin BioScience 6696.TWO | Taiwan | $3.98B | +305% | n/a | n/a | n/a | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.71B | +4% | -100% | n/a | n/a | n/a | n/a |
| JOINN Laboratories (China) 6127.HK | Hong Kong | $3.70B | +6% | +17% | -4% | 12.4× | n/a | n/a |
| Relay Therapeutics RLAY | United States | $3.65B | +27% | +24% | -3,095% | 273.1× | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.20B | -43% | +8% | -35% | 12.7× | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.60B | +141% | +92% | -298% | 43.4× | n/a | n/a |
| Disc Medicine IRON | United States | $3.55B | +16% | n/a | n/a | n/a | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.28B | -31% | +102% | 61% | 0.9× | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.47B | -13% | -13% | 21% | 4.5× | 2.2% | +12.5% |
| Iovance Biotherapeutics IOVA | United States | $3.46B | +111% | +51% | -61% | 8.3× | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.52B | -13% | -18% | -1% | 2.8× | 32.4% | +7.1% |
| Edgewise Therapeutics EWTX | United States | $4.53B | +26% | n/a | n/a | n/a | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.57B | -15% | -22% | 17% | 5.4× | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.32B | -25% | -54% | -6,983% | 6,626.2× | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.30B | +7% | n/a | n/a | n/a | n/a | n/a |
| Adaptive Biotechnologies ADPT | United States | $4.61B | +104% | +18% | -16% | 15.8× | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.73B | -5% | -12% | -8,684% | 1,432.1× | n/a | n/a |
| Hualan Biological Engineering 002007.SZ | China | $3.20B | -17% | -11% | 17% | 5.3× | 15.8% | -1.8% |
| Hangzhou Tigermed Consulting 3347.HK | Hong Kong | $4.75B | 0% | +22% | 10% | 4.8× | 25.4% | +15.6% |
| Virbac VIRP.PA | France | $3.20B | -4% | +4% | 15% | 2.1× | 5.8% | +9.4% |